Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Lilly

Option Trade Benefits From Steady Action In Eli Lilly Stock

The ideal scenario for this Lilly stock option trade for the stock to stay between 300 and 335 for the next two weeks.

Investors Business Daily

Executives Sell Over $100M Of 4 Stocks

Executives Sell Over $100M Of 4 Stocks

Gold futures traded lower this morning on Wednesday. Investors, meanwhile, focused on some notable insider trades.

Why Leaderboard And IBD 50 Stock Eli Lilly Just Became Actionable

Why Leaderboard And IBD 50 Stock Eli Lilly Just Became Actionable

Eli Lilly said Friday it will unveil new test results for its biggest cancer drug, Verzenio, in June and LLY stock broke out to a fresh high.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

The Daily Biotech Pulse: Setback For NRx Pharma's COVID Study, Fast Track Tag For Pfizer's NASH Combo Therapy, Reata's Ataxia Drug In FDA Review

Here's a roundup of top developments in the biotech space over the last 24 hours:

Lilly Touts Encouraging Mirikizumab Data In Ulcerative Colitis Maintenance Setting

Eli Lilly And Co (NYSE:LLY) announced a data readout for the Lucent-2 Phase 3 study of mirikizumab after 52 weeks. The trial enrolled patients with ulcerative colitis who had initially responded to mirikizumab in a 12-week Lucent-1 study. The primary endpoint was clinical remission, with 49.9% of participants in the mirikizumab arm reaching…

CHMP Backs Approval of Lilly/Incyte's Olumiant For Patchy Hair Loss

The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Eli Lilly And Co (NYSE:LLY) and Incyte Corporation's (NASDAQ:INCY) Olumiant (baricitinib) for severe alopecia areata (AA). If approved, Olumiant would be the first centrally-authorized oral treatment and first JAK inhibitor for severe AA in the European Union. …

Stock Market Rally Under Pressure As Walmart, Target Crash On Inflation Woes: Weekly Review

A newly confirmed stock market rally immediately came under heavy pressure as Walmart and Target warnings slammed the major indexes.

Investors Business Daily

inkl

Read news from The Economist, FT, and more,
with one subscription

Top-Rated Eli Lilly Nears Breakout After FDA Approves Its Next Potential Blockbuster

Top-Rated Eli Lilly Nears Breakout After FDA Approves Its Next Potential Blockbuster

The Food and Drug Administration approved an Eli Lilly diabetes drug it described as "novel," prodding LLY stock closer to a breakout.

Investors Business Daily

IBD Stock Of The Day Eli Lilly Is Eyeing Not One — But Two — Multibillion-Dollar Opportunities

IBD Stock Of The Day Eli Lilly Is Eyeing Not One — But Two — Multibillion-Dollar Opportunities

Eli Lilly is the IBD Stock Of The Day after "transformative" data in obesity helped LLY stock retain its recent breakout.

Investors Business Daily

IBD 50 Stocks To Watch: Medical Stock Eli Lilly Trades In Buy Zone After Reporting Promising Q1 Results

IBD 50 Stocks To Watch: Medical Stock Eli Lilly Trades In Buy Zone After Reporting Promising Q1 Results

With several core products showing strength, along with their Covid-19 antibodies, Eli Lilly updated their 2022 EPS guidance.

Investors Business Daily

Stock Market Volatile; Apple, Facebook, Amazon Are Key Earnings, Tesla CEO Elon Musk Buys Twitter: Weekly Review

Stock Market Volatile; Apple, Facebook, Amazon Are Key Earnings, Tesla CEO Elon Musk Buys Twitter: Weekly Review

A market rally attempt is underway, but the major indexes lost ground. Apple and Facebook led key earnings. Elon Musk will buy Twitter.

Investors Business Daily

Lilly's Tirzepatide Shows Up To 22.5% Weight Loss In New Phase 3 Readout

Lilly's Tirzepatide Shows Up To 22.5% Weight Loss In New Phase 3 Readout

Eli Lilly And Co (NYSE:LLY) reported topline results from SURMOUNT-1 Phase 3 trial evaluating Tirzepatide (5 mg, 10 mg, 15 mg) in obese patients with at least one comorbidity who do not have diabetes. Data exhibited that tirzepatide reduced patients' weights by an average of 16%, 21.4%, and 22.5% at the respective doses,…

Eli Lilly Achieves 80% Jump In COVID-19 Therapy Sales, Revises FY22 Guidance

Eli Lilly Achieves 80% Jump In COVID-19 Therapy Sales, Revises FY22 Guidance

Eli Lilly And Co (NYSE:LLY) has posted Q1 sales of $7.8 billion, beating the consensus of $6.68 billion. Lilly's revenue increased 15%, driven by volume growth of 20%, partially offset by a 3% decrease due to lower realized prices and a 2% decrease due to the unfavorable impact of foreign exchange rates. …

Eli Lilly Extends Its Breakout On First-Quarter Beat, Bullish News In Obesity

Eli Lilly Extends Its Breakout On First-Quarter Beat, Bullish News In Obesity

Eli Lilly topped first-quarter expectations and raised its sales outlook for 2022, prodding LLY stock to pop Thursday.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Will AbbVie And These Two Other Drug Stocks Reinvigorate — Or Incinerate?

A bullish first-quarter report could reinvigorate AbbVie stock, an analyst said Thursday after a C-suite setback this week.

Tribune News Service

Medicare’s strict Alzheimer’s policy raises ante for drugmakers

The U.S. Medicare program’s decision to tightly limit coverage for the first drug meant to slow the course of Alzheimer’s disease has raised the stakes for companies trying to make the next one.

Investors Business Daily

Will New Buys By The Best Mutual Funds Prop Up These Big-Name, But Pressured Stocks?

Making the latest list of new buys by the best mutual funds, Apple and GOOGL face headwinds, while Vertex and Lilly weather the storm.

Investors Business Daily

Vir Soars As Its Addition To SmallCap 600 Helps Wipe Out Recent Covid Volatility

GlaxoSmithKline's Covid treatment partner, Vir, will join the S&P SmallCap 600 next week, according to a report that sent Vir stock flying.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

As Eli Lilly Holds Above Breakout Level, Here Are Two Option Trade Ideas

The stock is trading above its 50-day and 200-day moving averages and those moving averages are sloping upward.

Investors Business Daily

How Rivals Merck, Bristol Myers Benefit From Eli Lilly's FDA Snag

The Food and Drug Administration on Thursday rejected a lung cancer drug Eli Lilly tested only in China, but LLY stock inched higher.

FDA Rejects Lilly's Sintilimab/Chemo Combo Therapy In First-Line Lung Cancer Setting

The Daily Biotech Pulse: Novartis Prostate Cancer Drug Lands FDA Approval, Ligand Announces SPAC Deal To Spin Off Antibody Business, Lilly's Lung Cancer Therapy Hit With CRL

Here's a roundup of top developments in the biotech space over the last 24 hours:

Eli Lilly To Suspend Sale Of 'Non-Essential' Medicines To Russia

Eli Lilly And Co (NYSE: LLY) said it would continue to supply drugs to Russia for urgent medical conditions such as cancer and diabetes but will suspend sales of "non-essential medicines."

Investors Business Daily

Top Funds Pump Money Into Eli Lilly As It Nears Breakout With Rising Relative Strength

With Eli Lilly earning a spot on the list of new buys by top funds, LLY stock is setting up a new buy point as the market correction continues.

Eli Lilly And 3 Other Stocks Sold By Insiders

Although US crude oil futures traded higher this morning, there were a few notable insider trades.

1 … 12 13 14 15

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Ulcerative Colitis

Places

265,313 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play